Healthcare / BiotechnologyNasdaqCM
$11.14
-0.37 (-3.21%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-174.5M · quality 49.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-40.6%
↓Gross Margin
N/A
•Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-34.6%
FCF CAGR
—
FCF margin
-380.0%
FCF / Net income
0.93x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $48.3M · net income $-196.4M · FCF $-183.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $48.3M | $48.3M | $155.8M | $54.0M | $172.8M |
| Net Income | $-196.4M | $-196.4M | $15.2M | $-94.6M | $27.7M |
| EBITDA | $-185.1M | $-185.1M | $34.5M | $-88.9M | $50.0M |
| EPS | — | — | 0.14 | -1.18 | 0.55 |
| Operating Margin | -377.1% | -377.1% | -24.8% | -188.4% | 17.3% |
| Net Margin | -407.0% | -407.0% | 9.8% | -175.3% | 16.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.03 | 0.07 | 0.07 |
| Current Ratio | 8.78 | 8.78 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-183.4M | $-183.4M | $-174.5M | $-12.7M | $93.9M |
| Returns | |||||
| ROE | -40.6% | -40.6% | 2.6% | -43.5% | 13.6% |
| Valuation | |||||
| P/E | — | — | 51.21 | — | 17.16 |
| EV/EBITDA | — | — | 15.82 | — | 10.19 |
| P/B | 3.09 | 3.09 | 1.33 | 3.86 | 3.17 |
| Growth & Yield | |||||
| Revenue Growth | -69.0% | -69.0% | 188.6% | -68.8% | — |
| EPS Growth | — | — | 111.9% | -314.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+106.7%
Start / end P/E
n/dx → n/dx
EPS bridge
0.14 → n/d
Residual
+106.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.